echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Novo Nordisk launches clinical trials of long-acting insulin in China once a week

    Novo Nordisk launches clinical trials of long-acting insulin in China once a week

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The latest announcement of the Chinese drug clinical trial registration and information disclosure platform, Novo Nordisk launched a trial in China to study the pharmacokinetic characteristics of icodec insulin in Chinese subjects with type 2 diabetes, aiming to evaluate icodec insulin injections The stay and changes in the patient’s blood over time after administration.


    Icodec insulin was developed by scientists at Novo Nordisk by modifying the insulin molecule.


    The clinical study initiated by icodec insulin in China is a single-arm, open, phase 1 trial to study how a new type of long-acting insulin (icodec insulin) works in the body of subjects with type 2 diabetes in China.


    According to the results of the icodec insulin phase 2 clinical trial published by Novo Nordisk, compared with the once-daily injection of insulin glargine U100, adult patients with type 2 diabetes who injected icodec insulin showed good efficacy and tolerance.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.